Abstract : Fifty-one resected advanced gastric cancer patients who had preoperative chemotherapies, consisting of oral administration of 5-fluorouracil (5-FU) and 5-FU/ cisplatin intravenous administration, were included in the present study. The rate of thymidylate synthetase inhibition (TSIR) was measured in resected tissues. Proliferating cell nuclear antigen expression (PCNA-S) and the rate of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling expression (TUNEL-I) were also investigated in gastric cancer tissues obtained before and after chemotherapy. The aim of the present study was to examine whether these parameters were reliable prognostic indicators in these patients. Five-year survival analysis showed that a higher value of TSIR significantly predicted a better prognosis. A multiple regression analysis showed that TSIR and the conclusive stage were significant predictive indicators for prognosis in these patients. In curatively resected patients, TSIR was the only significant prognostic indicator. Therefore, TSIR in gastric cancer tissue is a useful indicator for predicting the efficacy of preoperative chemotherapy.
Introduction
The concept of preoperative chemothrapy for advanced gastric cancer patients with severe locoregioinal spread has come to increasing in recent years since surgery alone has not been fully effective for these patients1). Preoperative chemotherapeutic regimens that include 5-fluorouracil (5-FU) have been shown to be suitable for potentially resectable advanced gastric cancer patients2, 3) . A Japanese Classification of Gastric Carcinoma includes an evaluation of the histopathological as well as clinical response to preoperative chemotherapy 4). However, other indicators that evaluate the response to preoperative chemother-apy are required, and indicators assessing the prognosis after preoperative chemotherapy are also needed, when preoperative chemotherapy is performed on potentially resectable patients and is performed just before surgery.
The present study examined three potential indicators which may assess the chemotherapeutic response or the prognosis after preoperative chemotherapy. The first is the rate of thymidylate synthetase inhibition (TSIR) in cancer tissue obtained after preoperative chemotherapy, which indicates the degree of inhibition of DNA synthesis by 5-FU5). The TSIR has been shown to be a useful biochemical parameter for the evaluation of 5-FU chemotherapeutic response6, 7). The second is the suppression of proliferating cell nuclear antigen expression (PCNA-S) , which is measured in cancer tissue specimens obtained before and after preoperative chemotherapy. PCNA is detected at the proliferating phase in the cell cycle, and could be another quantitative parameter for the evaluation of preoperative chemotherapeutic response in gastric cancer tissues8-10). The third is an index of cancer cell apoptosis induced by preoperative chemotherapy, which is measured by terminal deoxynucleotidyl transferase (TdT) -mediated deoxyuridine triphosphate (dUTP) -biotin nick end labeling (TUNEL-I)11) . There is a growing body of evidence to show that the efficacy of various antitumor agents is related to the susceptibility of the target tumor cells to apoptosis 12). The detection of DNA fragmentation by the TUNEL method has been shown to be a more sensitive method for assessing apoptosis than conventional morphological techniques 13). Three hundred mg/day of 5-FU was administered for 14 days, and 100 mg was orally administered on the day of surgery. The other 21 patients received 5-FU and cisplatin (CDDP) intravenously (5-FU/CDDP). Five days' serial administration of 5-FU just before surgery was performed (500 mg/m2). CDDP was administered on day 3 (50 mg/m2). Five hundred mg/ m2 of 5-FU was intravenously administered on the day of surgery. In the cases of oral 5-FU administration, 5-FU was administered up to the morning of the operation. In the cases of 5-FU/CDDP therapy, 5-FU was administered by drip infusion right up to the beginning of surgery. TUNEL-I : To measure the difference in the TUNEL labeling index (TUNEL-LI) between prechemotherapy and postchemotherapy (i.e., TUNEL-I ), half of each fresh cancer tissue specimen was fixed for 24 hours in 20% phosphate-buffered formalin and embedded in paraffin, and the endoscopically obtained tissues were also used. The TUNEL immunocytochemical expression was performed by the immunocytochemical method described previously 14). A newly developed kit, the Mebstain apoptosis kit (code no. 8440; Medical and Biological Laboratories Co., Nagoya, Japan) was used. The TUNEL labeling index in cancer tissue was given by the number of TUNEL-positive cells per 1000 cancer cells, and TUNEL-I was calculated as : ( Unpaired two-group comparisons were made by the Mann-Whitney U nonparametric test. Survival time was calculated from the date of gastrectomy until death. The cumulative 5-year survival rate was estimated by the method of Kaplan and Meier. The logrank test was used to assess the significance. A univariate Cox's proportional hazard model was used to calculate the relative risk of mortality and 95% confidence intervals. A multivariate stepwise Cox's regression analysis (backward elimination method) was performed to identify factors that were independently associated with mortality. All statistical analyses were performed using the software package Statview IV (Abacus Concepts, Berkley, CA, USA). The survival analysis was made by the Statview IV equipped with Survival Tools (Abacus Concepts). When the p-value in any analysis was less than 0.05, the difference was considered to be significant.
Results
The Multiple regression analysis of stage Ib-IVb patients showed that the conclusive stage and TSIR were significant prognostic indicators (Table 3 ; p = 0.006 and p = 0.035, respectively). In the Ib-IVa curatively resected patients, another multiple regression analysis showed that TSIR was the only significant prognostic indicator ( Five-year survival rate of the 5-FU oral administration group was 31.4%, and that in the 5-FU/CDDP group was 31.7% in the stage Ib-IVb patients. On the other hand, 5-year survival rate in patients without preoperative chemotherapy, but with adjuvant chemotherapy of 5-FU/CDDP every 4 weeks after the diagnosis of recurrence, was 25.4% (n=88 ; stage Ib-IVb). The preoperative chemotherapy increased survival rate, but not significantly. The present study examined two regimens of preoperative chemotherapy. The effectiveness of 5-FU oral administration in the treatment of gastrointestinal cancers may be questionable, since the absorption of 5-FU through the gastrointestinal tract is variable and inconsistent 26). However, Phillips et al. demonstrated the efficacy of 5-FU oral administration because of its high concentration in the portal blood 27) . In the present study, the concentrations of FdUMP (an active form of 5-FU) in the cancer tissue were not different between the 5-FU oral administration group and the 5-FU /CDDP group. The finding suggests that the two regimens of preoperative chemotherapy provided equivalent delivery of 5-FU to cancer tissue. In addition, higher values of TSIR in both 5-FU oral administration and 5-FU/CDDP groups predicted better survival. These findings suggest the efficacy of both these regimens of preoperative chemotherapy. 
